PDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 28(Supplement_3): 161-166 2008
© 2008 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tranæus, A.
Right arrow Articles by Yao, Q.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tranæus, A.
Right arrow Articles by Yao, Q.

Part 7: Immunodysfunction and Peritonitis in PD

IMMUNE DYSFUNCTION IN DIALYSIS PATIENTS—PREVENTION AND TREATMENT STRATEGIES

Anders Tranæus and Qiang Yao

Baxter RenalDivision, Asia Pacific, Shanghai, PR China

Correspondence to: Anders Tranæus, Baxter Renal Division, Asia Pacific, 10F Platinum Tower, 233 Tai Cang Road, Shanghai 200020 PR China.
tranaea{at}baxter.com

Immune dysfunction, resulting in infection or inflammation, or both, is closely associated with poor clinical outcome in end-stage renal disease patients. So far, no single measure can effectively address this condition, because many factors, such as uremia per se and dialysis treatment are involved in the pathogenesis. Our review focuses on currently available treatments and prevention options, and identifies future research needs.

KEY WORDS: Inflammation; infection; end-stage renal disease.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 2008 by Multimed Inc.